GP
ABEO icon

GLG Partners’s Abeona Therapeutics ABEO Stock Holding History

GLG Partners’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-497
Closed -$62K – 325
2017
Q1 		$62K Sell
497
-1,035
-68% -$133K ﹤0.01% 434
2016
Q4 		$186K Buy
+1,532
New +$240K 0.01% 352
2016
Q1 		– Sell
-5,165
Closed -$434K – 402
2015
Q4 		$434K Buy
+5,165
New +$518K 0.01% 377

Other funds holding ABEO

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

GLG Partners's ABEO Position: Q2 2017 in Review

GLG Partners sold out of Abeona Therapeutics (ABEO) in Q2 2017, closing a stake of 497 shares — an estimated $62K sold.

GLG Partners first reported a position in ABEO in Q4 2015 and held it in 3 quarters. The position peaked at $434K in Q4 2015. 70 funds tracked by Wall St. Rank hold ABEO as of Q2 2017.

  • GLG Partners reported no remaining Abeona Therapeutics position as of Q2 2017 after selling out during the quarter.
  • GLG Partners sold 497 Abeona Therapeutics shares in Q2 2017, an estimated $62K.
  • GLG Partners first reported a position in Abeona Therapeutics in Q4 2015 and held it in 3 quarters.
  • GLG Partners's Abeona Therapeutics position peaked at $434K in Q4 2015.
  • 70 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2017.

Based on GLG Partners's 13F filing for Q2 2017, filed 14 Aug 2017.